On April 2, 2019, Whitefort Capital Management, LP delivered a letter to the Board of Directors of Novelion Therapeutics Inc. expressing its concerns over a potential restructuring of Aegerion Pharmaceuticals, Inc., a wholly owned subsidiary of the Company.